Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.
Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, Keeney F, Nathanson KL, Herlyn M. Vultur A, et al. Among authors: krepler c. Oncogene. 2014 Apr 3;33(14):1850-61. doi: 10.1038/onc.2013.131. Epub 2013 Apr 29. Oncogene. 2014. PMID: 23624919 Free PMC article.
The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, McKinlay M, Herlyn M. Krepler C, et al. Clin Cancer Res. 2013 Apr 1;19(7):1784-94. doi: 10.1158/1078-0432.CCR-12-2518. Epub 2013 Feb 12. Clin Cancer Res. 2013. PMID: 23403634 Free PMC article.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, DeMarini DJ, Gilmer TM, Martin AM, Marmorstein R, Schultz DC, Speicher DW, Karakousis GC, Xu W, Amaravadi RK, Xu X, Schuchter LM, Herlyn M, Nathanson KL. Villanueva J, et al. Among authors: krepler c. Cell Rep. 2013 Sep 26;4(6):1090-9. doi: 10.1016/j.celrep.2013.08.023. Epub 2013 Sep 19. Cell Rep. 2013. PMID: 24055054 Free PMC article.
Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.
Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A. Shannan B, et al. Among authors: krepler c. Pigment Cell Melanoma Res. 2016 May;29(3):317-28. doi: 10.1111/pcmr.12465. Epub 2016 Mar 21. Pigment Cell Melanoma Res. 2016. PMID: 26850518 Free PMC article.
PIM kinases as therapeutic targets against advanced melanoma.
Shannan B, Watters A, Chen Q, Mollin S, Dörr M, Meggers E, Xu X, Gimotty PA, Perego M, Li L, Benci J, Krepler C, Brafford P, Zhang J, Wei Z, Zhang G, Liu Q, Yin X, Nathanson KL, Herlyn M, Vultur A. Shannan B, et al. Among authors: krepler c. Oncotarget. 2016 Aug 23;7(34):54897-54912. doi: 10.18632/oncotarget.10703. Oncotarget. 2016. PMID: 27448973 Free PMC article.
Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma.
Krepler C, Xiao M, Samanta M, Vultur A, Chen HY, Brafford P, Reyes-Uribe PI, Halloran M, Chen T, He X, Hristova D, Liu Q, Samatar AA, Davies MA, Nathanson KL, Fukunaga-Kalabis M, Herlyn M, Villanueva J. Krepler C, et al. Oncotarget. 2016 Nov 1;7(44):71211-71222. doi: 10.18632/oncotarget.12078. Oncotarget. 2016. PMID: 27655717 Free PMC article.
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J. Echevarría-Vargas IM, et al. Among authors: krepler c. EMBO Mol Med. 2018 May;10(5):e8446. doi: 10.15252/emmm.201708446. EMBO Mol Med. 2018. PMID: 29650805 Free PMC article.
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE. Wang T, et al. Among authors: krepler c. Clin Cancer Res. 2015 Apr 1;21(7):1652-64. doi: 10.1158/1078-0432.CCR-14-1554. Epub 2015 Jan 23. Clin Cancer Res. 2015. PMID: 25617424 Free PMC article.
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M. Krepler C, et al. Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16. Clin Cancer Res. 2016. PMID: 26673799 Free PMC article.
87 results